Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-Val Development Program in Patients With Relapsed or Refractory Ebv-Positive Peripheral T-Cell Lymphoma
Viracta Therapeutics宣佈重新調整資源，以加強對復發或難治EBV陽性外周T細胞淋巴瘤患者的Nana-Val開發計劃的關注
